This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kimko, H.
Right arrow Articles by Noel, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimko, H.
Right arrow Articles by Noel, G. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2009, p. 1228-1230, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.00632-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Population Pharmacokinetic Analysis of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections{triangledown}

Holly Kimko,* Bindu Murthy, Xu Xu, Partha Nandy, Richard Strauss, and Gary J. Noel

Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJ

Received 14 May 2008/ Returned for modification 28 September 2008/ Accepted 5 December 2008

Population pharmacokinetic analysis demonstrated that renal function, as assessed by creatinine clearance (CLCR), was the patient characteristic that had a clinically relevant impact on ceftobiprole pharmacodynamics. Dosing adjustments based on CLCR for subjects with renal impairment should provide ceftobiprole exposure similar to that in patients with normal renal function.

* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research & Development, LLC, 920 Route 202, South Raritan, NJ 08869. Phone: (908) 704 5577. Fax: (908) 203 1527. E-mail: HKimko{at}its.jnj.com

{triangledown} Published ahead of print on 15 December 2008.

Antimicrobial Agents and Chemotherapy, March 2009, p. 1228-1230, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.00632-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Zhanel, G. G., Voth, D., Nichol, K., Karlowsky, J. A., Noreddin, A. M., Hoban, D. J. (2009). Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 64: 364-369 [Abstract] [Full Text]  
  • Kimko, H., Xu, X., Nandy, P., Samtani, M. N., Strauss, R. S., Bagchi, P., Noel, G. J. (2009). Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 53: 3371-3374 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»